Composition for antibiotically therapy


(57) Abstract:

The invention relates to medicine and can be used in Oncology for chemotherapy of malignant tumors. Based on the established fact increase antibiotically activity of platinum coordination compounds when used in combination with 1,10-phenanthroline and ascorbic acid determined the composition consisting of the indicated substances in a weight ratio of 1: 1: 1-1: 1:10. The composition shows a marked increase antitumor cytotoxic activity, indicating that the regularities of the effect of potentiation. 3 table.

The invention relates to medicine and can be used in Oncology for chemotherapy of malignant tumors.

In chemotherapy of malignant tumors are widely used coordination compounds of platinum /1/, /2/.

A significant drawback of these drugs is relatively low efficiency, limited by their toxic side effects.

The problem solved by the invention is a drug on the basis of platinum coordination compounds with high anti-tumor activity.

Problem solved p the m ratio 1:1: 1-1:1:10.

Used in the work the following coordination compounds of platinum:

1) CIS-dichlorodiammineplatinum(CIS-DDP, cisplatin);

2) sodium dichloro-N, N, N, N - tetrakis(2-amino-ethyl)-1,6 hexamethylenediaminetetra (Pt2ACl4);

3; K2PtCl4.

The study antibioticheskih action of the composition is conducted in vitro and in vivo.

Example 1.

Study and evaluation of antibiotically activity of drugs in vitro held in suspension cultures of leukemic cell line K-562 and leukemia Rausher (2,5105cells /ml) inclusion of3H-uridine and3H-thymidine after 24-48 h of incubation. Radioactivity measurements carried out on a beta counter Mark-III.

The composition was obtained by mixing solutions of these components.

The results are shown in table.1 and 2.

As can be seen from the table.1 and 2, in terms of combined use with phenanthrolin-ascorbate system platinum drugs have a more pronounced suppression of proliferation of tumor cells in comparison with the data from those experiments, where the platinum compounds were used in isolation.

Example 2.

Toxicological characteristics of 1,10-phenanthroline studied 50 Mysore in respect of 1,10-phenanthrolin:ascorbic acid, equal to 1:10.

Value sredneseriynoe dose 1,10-phenanthroline (LD50) was 83 mg/kg (LD50for CIS-DDP is 13.5 mg/kg, for Pt2ACl440 mg/kg).

Simultaneous administration to mice of 1,10-phenanthroline and ascorbic acid was not accompanied by increased toxic reactions and the increase in the percentage of death of the experimental animals (table.3).

Example 3.

The study antibiotically activity of platinum compounds in combination with 1,10-phenanthroline (PR) and ascorbic acid (C) conducted at 250 BALB/c mice with leukemia Rausher, mastocytoma P-815 and Ehrlich carcinoma after 48 h after intraperitoneal inoculation of tumors (7106cells/mouse).

Example 3.1 a Single intra-abdominal injection of CIS-DDP at a dose of 7 mg/kg in combination with 1,10-phenanthroline and ascorbic acid (total dose of 360 mg/kg) was accompanied by a statistically significant increase in life span of mice (each group of 15-20 animals): CIS-DDP mg/kg+(PR+) mg/kg - 40,30,9 days; CIS-DDP 7 mg/kg - 34,60,5 days; RR+S - 28,40,7 days; control gr. - 25,50,6 days. In each group of 15-20 animals.

Single injection of mice with tumor-P-815 Pt2ACl4at a dose of 25 mg/kg in combination with the PR: (Sommarplaga that in terms of the stand-alone application (without the PR-C) drug and control (25,50,6 days).

3.2. In terms of the four-course introduction to mice with leukemia Rauser Pt2ACl4in the dose of 10 mg/kg in combination with the PR-WITH a dose of 220 mg/kg lifespan of experimental animals has increased dramatically ( up to 117,31,8 days), at 269 % of control (31,80,2) and 150% of the group, where binuclear platinum was used without the PA system: (68,40,7 days).

3.3. In exchange triple the introduction of combination products K2PtCl4:OP: C in a total dose of 50 mg/kg to mice with Ehrlich carcinoma, as in the previous series of experiments, there was an increase in life expectancy of animals to 39,81,3 days, in the control -20,60,9 days, i.e., 93.2%, whereas in case of separate application components, life expectancy increased by only 5-7% of the control.

Thus, the analysis of data obtained in all series of experiments, allows us to conclude that in case of joint application combination phenanthroline, ascorbic acid and coordination compounds of platinum is observed (statistically significant) expressed increasing antitumor cytotoxic activity of the latter, indicating the regularity of the effect of potentiation.

Sources of information

1. Cyclopean, edited by I. K. Bublemichael therapy based on coordination compounds of platinum, characterized in that, along with the coordination compound of platinum it contains 1,10-phenanthrolin and ascorbic acid at a weight ratio of 1: 1: 1-1: 1: 10.


Same patents:

The invention relates to medicine and applies betterin-1,3-dioxide (BTDA) and bromo derivatives as inhibitors of platelet aggregation with antimetastatic action

The invention relates to new derivatives isoxazol and amide crotonic acid of General formula I, where R1denotes a residue of formula II or III, R2denotes-O-(CH2)n-CH= CH2n designates an integer of 1-3, -O-(CH2)m-CH2is halogen, m represents an integer of 1-3, halogen denotes fluorine, chlorine, bromine or iodine, a residue of the formula V, where3denotes halogen or NH2, R4denotes a hydrogen atom, and/or their physiologically acceptable salts

The invention relates to compounds of formula (I), where R1and R2are cycloalkyl group, aryl group, heterocyclic group; R3and R4is a hydrogen atom or alkoxygroup; R5is a hydrogen atom, alkyl; R6the hydroxy - group, alkoxygroup, allylthiourea or amine residue, X and Y are an oxygen atom; Z represents a single bond between the said nitrogen atom and the benzene ring or alkilinity group G is a direct bond, alkyl, alkylen, the dotted line indicates a single or double bond, D is a carbon atom; E - =N-O-group
The invention relates to medicine

The invention relates to new compounds of General formula I, in which R is selected from the group consisting of R2, R2NH or H2N-R3 where R2 is selected from the group consisting of C1-C8the alkyl and formula (II), where Z is selected from the group consisting of phenyl, heterocycle and cycloalkyl, each R4 independently represents hydrogen or C1-C4alkyl, and n is an integer equal to 1 to 8; where each1-C8alkyl, and Z optionally substituted by 1-3 substituents, which may be the same or different, selected from the group consisting of Hal, HE and1-C4of alkyl; R3 represents C1-C8alkylene; and R1 is selected from the group consisting of cyclopentyl and isopropyl, and their pharmaceutically acceptable salts, optical isomers and hydrates

The invention relates to derivatives of 4-mercaptopyridine formulae of the following classes of i), ii) and iii), represented by the following formula:

< / BR>
where X1means N; C1-6alkoxyl1-6alkyl; C1-6alkoxyl1-6alkylsulphonyl; And means phenyl, naphthyl; X2means H, phenyl, phenyl WITH1-6alkyl; X3means N; C1-6alkyl; X4means1-6alkylsulfanyl, carbarnoyl;

< / BR>
where X5means-C(O)-C1-4alkyl-Phenyl; -C(O)-C1-6alkyl; -C(O)-C1-4alkylpyridine, and Ph and pyridyl optionally substituted C1-4the alkyl, C1-4alkoxy, C1-4alkalosis1-4by alkyl; a represents naphthyl; R3selected from the group comprising H; HE; NO2; -(CH2)nCOOR8where n is 0 to 3 and R8represents H, C1-4alkyl, C2-4alkenyl; -CONR9R10where R9and R10independently represent H, C1-4alkyl, C2-4alkenyl, -CON(R11OR12where R11and R12independently represent H, C1-4alkyl and C2-4alkenyl; a group of formula II: -CONR13-CHR14-COOR17where R13made the>alkyl; p is 0 to 3, and R3may be the same or different;

< / BR>
where X6has any value defined above for X5in ii); X7is Ph, optionally substituted by substituent (substituents), selected from the group comprising FROM1-4alkoxy; a represents Ph or naphthyl; R3and R such as defined above, or its N-oxide, MES, ester, pharmaceutically acceptable salt

The invention relates to medicine, namely to gynecology, and can be used to treat ovarian cancer

The invention relates to experimental medicine and relates to methods of modeling oppression hormonal activity of the ovaries

The invention relates to medicine, in particular to methods for antitumor compositions on the basis of fluorouracil, intended for injection

The invention relates to new derivatives of 6-arrepiado[2,3-d]pyrimidine and-naphthiridine, their pharmaceutically acceptable salts, pharmaceutical composition having inhibitory effect of cell proliferation caused by protein tyrosinekinase, and to a method of inhibiting cell proliferation

The invention relates to coordination compounds of metals exhibiting cytotoxic activity and can be used in medicine and veterinary medicine for the purpose of chemotherapy

The invention relates to compounds of General formula I

< / BR>
in which X represents a hydrogen atom or halogen, (C1-C3)alkyl group, one or two (C1-C3)alkoxy group, or triptorelin group, Y is a hydrogen atom or halogen, (C1-C3)alkyl or (C1-C3)alkoxygroup, R represents a hydroxy group, a methoxy group, or a group of the General formula NR2R3in which R2and R3each independently represents a hydrogen atom, (C1-C4)alkyl group, 2-methoxyaniline group, 3-methoxyaniline group, 3-aminopropyl group, group 2-(dimethylamino)ethyl group, 3-(dimethylamino)propyl or 2-piperidine-2-retil, or R2and R3form together with the nitrogen atom to which they are connected, morpholine, pyrolidine or pieperazinove ring which may have in position 4 Deputy in the form of a methyl group or groups (1,1-dimethylmethoxy)carbonyl, in the form of free bases or salts formed by the addition of acid
The invention relates to medicine, namely to ophthalmology, and is intended for the treatment of inflammatory diseases of the iris and ciliary body, accompanied fibrinous exudation

The invention relates to medicine and relates to pharmaceutical compositions containing non-steroidal anti-inflammatory compound, at least one connection, reinforcing its pharmacological action, selected from dibasic carboxylic acids, ammonium succinate, amino acids, salts, vitamins, polyphenolic compounds and products containing animal and vegetable origin, as well as the target additive, representing a carbohydrate or sorbent

The invention relates to the field of medicine
The invention relates to chemical-pharmaceutical industry, namely the creation of a multivitamin preparation with mineral additives
The invention relates to the pharmaceutical industry that produces drugs for the lack of breast milk in lactating women, burdened with the obstetric history and hypogalactia, with malnutrition and anorexia in infants and young children
The invention relates to chemical-pharmaceutical industry, namely soluble effervescent tablets for oral administration and method of production thereof

The invention relates to medicine and food industry, namely the production of vitamin and antioxidant complexes with high biological activity with therapeutic-preventive effect

The invention relates to pharmaceutical industry